Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects With Renal Impairment and Matched Control Subjects With Normal Renal Function

Next Previous
Search
Trial Profile

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects With Renal Impairment and Matched Control Subjects With Normal Renal Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonefpeglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Pharmacokinetics
  • Sponsors Hanmi Pharmaceutical

    • Most Recent Events

    • 23 Dec 2024 According to Hanmi Pharmaceutical the Media Release, company announced results of this trial at the European Society of Clinical Nutrition and Metabolism (ESPEN) held in Milan, Italy in September.
    • 05 Sep 2024 According to Hanmi Pharmaceutical the Media Release, company will present the pharmacokinetic clinical results from this study at the European Society of Clinical Nutrition and Metabolism (ESPEN) held in September.
    • 01 Dec 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top